Wednesday, April 19, 2017

EpicGenetics Announces Major Clinical Study to Locate Genetic Markers Unique to People with Fibromyalgia and Explore New Treatment Approaches



EpicGenetics, with the Assistance of Leading Medical Centers, Expands Clinical Study of FM/a® Test to Diagnose Fibromyalgia, Identify Genetic Markers Unique to the Disorder and Explore Direct Treatment Approaches

- Provides Research Gift to the Faustman Immunobiology Lab at
Massachusetts General Hospital/Harvard Medical School to
Support Research on Fibromyalgia Treatments -

In February of 2016, I wrote a blog on the importance of a well-designed study on fibromyalgia, Are Fibromyalgia Researchers on a Common Path?

In June of 2016, I wrote a blog on my personal experience with the FM/a® blood test providing a detailed guideline on how the process worked for me, and my results.

In an article that will be published soon by ProHealth, I write about the chaos surrounding concrete diagnostic criteria and the disparaging consequences.

Breaking News

And now I am excited to write about new research that could very well provide us with a true understanding of a “disease” called fibromyalgia.

I have been waiting for permission to share what you are about to read.

LOS ANGELES – April 19, 2017 – EpicGenetics, a privately held biomedical company dedicated to improving the diagnosis and treatment of fibromyalgia, today announced that it has engaged the University of California, Los Angeles (UCLA)* and the University of Illinois College of Medicine Chicago (UIC). Both university research centers will be sequencing the exomes of patients to improve the diagnosis of fibromyalgia through the application of the FM/a® Test and to allow EpicGenetics to detect fibromyalgia disease-specific gene markers. Additionally, Bruce Gillis, M.D., CEO of EpicGenetics, has made a research gift to the Immunobiology Laboratory at the Massachusetts General Hospital directed by Denise Faustman, M.D., Ph.D., to continue its robust clinical research regarding a direct treatment for fibromyalgia. 

The FM/a® Test is an FDA-compliant blood test that diagnoses fibromyalgia by identifying the presence of specific white blood cell abnormalities that have been documented to exist in these patients. The FM/a® Test accurately and objectively diagnoses this chronic disorder that afflicts millions of men, women and children.


Committment

I have been committed to understanding and educating my peers on fibromyalgia over the past two decades, but I have never been as excited as I am right now. To be part of a study that has the potential to prove fibromyalgia as a disease with definite treatments is probably the pinnacle of my work.

Dr. Gillis Is Committed

About this announcement, Dr. Gillis told me, “We are hoping to finally bring our understanding of fibromyalgia out of the Dark Ages. Millions of women, men and children suffer from fibromyalgia, yet our understanding and acknowledgement of this as a legitimate medical condition is still so limited and has not advanced in a meaningful way in decades. With the clinical efforts being initiated as part of today’s announcement, we hope to finally change this and, ultimately, we are seeking to provide answers and better solutions for people who suffer from fibromyalgia.”

Follow @TheFMTest on Facebook

What is “Campaign 250?”

According to Epicgenetics, Campaign 250 represents the largest and most ambitious study to investigate fibromyalgia’s genetic origins, as well as develop a treatment protocol addressing the underlying biology of the disease.

Download PDF at
https://drive.google.com/file/d/0B6iFloW6MyVwakttOHFGUWpRNkk/view?usp=sharing


Under contract with researchers from both UCLA* and the University of Illinois College of Medicine Chicago, Campaign 250 will conduct Whole-Exome genetic testing on up to 250,000 patients who have received a positive FM/a® fibromyalgia diagnosis. All direct testing costs will be covered by EpicGenetics**. Based upon the findings of this testing and once treatment protocols have received regulatory and institutional approvals, FM/a® Test positive patients will be invited to participate in a fibromyalgia-specific vaccine clinical trial to reverse the biology of fibromyalgia. The vaccine trial will be conducted in cooperation with The Faustman Lab and Dr. Denise Faustman at the Massachusetts General Hospital/Harvard School of Medicine, the clinical trial will seek to alleviate fibromyalgia-related symptoms…

* The David Geffen School of Medicine at UCLA has been engaged to sequence the exomes of research subjects
**The genetic tests will require a $45 administration fee to cover the processing of the test, which is a $2,500+ cost being provided at no charge. 

Participation

I am anxious to see if I carry the fibromyalgia gene and I am honored to participate in providing information that can make a difference in the lives of people all over the world who live with fibromyalgia. I hope you can join me on this next chapter.




“The mighty oak was once a little nut that stood its ground.”
--Unknown


Additional Information:
FM/a® Blood Test – “How To” – My detailed account of the process

In healing,,Celeste

"Adversity is only an obstacle if we fail to see opportunity."

~ • ~ • ~ • ~ • ~ • ~

Celeste Cooper, RN
Author—Patient—Freelance Writer at Health Central & ProHealth Advocate

Celeste’s Website: http://CelesteCooper.com

Learn more about Celeste’s books at her website or find links here on Celeste's  blog. Subscribe to posts by using the information in the upper right hand corner or use the share buttons to share with others.

All blogs and comments are based on the author's opinions and are not meant to replace medical advice.  





No comments:

Celeste's Website

Celeste's Website
Click on the picture